COVID Vaccine and Prion Disease: What the Classen Paper Says
Short answer
In a 2021 paper, J. Bart Classen analysed the Pfizer COVID-19 vaccine RNA and the spike protein it makes. He reported sixteen UG tandem repeats and two GGΨA sequences that may cause the proteins TDP-43 and FUS to fold into their disease-causing prion shapes, plus a zinc pathway through ACE2. He concluded approval was premature.

Key takeaways
- 1Classen analysed the Pfizer vaccine's RNA sequence and the spike protein's interaction with ACE2 for the potential to trigger prion-based disease.
- 2He reported sixteen UG tandem repeats (ΨGΨG), additional UG-rich sequences and two GGΨA sequences, patterns published studies link to TDP-43 and FUS binding.
- 3He wrote that G-quadruplex sequences are possibly present but that more sophisticated software is needed to verify them.
- 4He proposed that spike binding to ACE2, a zinc-containing enzyme, could raise zinc inside cells, and zinc has been shown to make TDP-43 form amyloid-like aggregates.
- 5He concluded that regulatory approval of the RNA vaccines was premature and that the vaccine may cause more harm than benefit.
A 2021 paper by J. Bart Classen reports that the Pfizer COVID-19 vaccine RNA contains sequences that may push the proteins TDP-43 and FUS into the prion shapes linked to neurodegenerative disease. The evidence is an analysis of the RNA sequence and the spike protein, not a study of vaccinated people. This guide walks through the paper section by section: what was analysed, what was found and what the author concluded.
Next step
Want vaccine and prion research explained in plain language?
Explore our plain-English guides on spike protein, amyloid and neurodegeneration.
What is the paper?
It's COVID-19 RNA Based Vaccines and the Risk of Prion Disease by J. Bart Classen, MD, of Classen Immunotherapies. It was published in Microbiology & Infectious Diseases, volume 5, issue 1, pages 1 to 3. It was received on December 27, 2020 and accepted on February 8, 2021.
The paper evaluated the Pfizer COVID-19 vaccine for the potential to induce prion-based disease in people who receive it.
Why did the author look at this?
Classen opens by noting that vaccines have been found to cause chronic, late-developing adverse events. He gives type 1 diabetes as an example, which he writes may not appear until 3 to 4 years after a vaccine is given.
He also writes that new vaccine technology creates new possible ways for adverse events to happen. His example is the first killed polio vaccine, which caused polio in some recipients because the scaled-up manufacturing didn't fully kill the virus.
Because the Pfizer vaccine was authorised by the US FDA under an emergency use authorization without long-term safety data, he set out to check whether it could induce prion-based disease.
What are prions, TDP-43 and FUS?
A prion is a protein that folds into a harmful shape. The paper focuses on a class of RNA-binding proteins that research has linked to neurological diseases, including Alzheimer's disease and ALS. TDP-43 and FUS are among the best studied of these, according to a 2012 review of RNA-binding proteins with prion-like domains.
The paper explains that these proteins:
- Are found in both the nucleus and the cytoplasm of cells
- Have binding regions that grab specific RNA sequences
- Are believed to fold in certain ways when they bind certain RNA in the cytoplasm
- Can then clump together and form prions
Classen writes that TDP-43 and FUS folding into their pathologic prion shapes is known to cause ALS, frontotemporal lobar degeneration, Alzheimer's disease and other neurodegenerative diseases.
How was the vaccine analysed?
The paper used two approaches:
- The RNA sequence. The vaccine's RNA was checked for sequences known to activate TDP-43 and FUS.
- The spike protein. The interaction between the spike protein the vaccine RNA makes and its target, ACE2, was analysed to see whether it could also activate TDP-43 and FUS.
What did the RNA sequence analysis find?
Classen cites published studies showing that certain RNA patterns bind TDP-43 or FUS more strongly and may push them into their pathologic shapes in the cytoplasm. Here's what each pattern is and what he reported in the vaccine:
| RNA pattern | Study the paper cites | What Classen reported in the vaccine |
|---|---|---|
| GGUA sequences | Kapeli et al., 2016 | 2 GGΨA sequences |
| UG-rich sequences | Kuo et al., 2014 | Additional UG-rich (ΨG) sequences |
| UG tandem repeats | Tollervey et al., 2011 | 16 UG tandem repeats (ΨGΨG) |
| G-quadruplex sequences | Imperatore et al., 2020 | Possibly present; a more sophisticated computer program is needed to verify |
In plain terms: think of these RNA patterns as hooks. TDP-43 and FUS like to grab those hooks. Classen counted the hooks in the vaccine RNA and concluded it contains many of the sequences shown to have high affinity for TDP-43 or FUS.
The Ψ symbol in the table stands for the modified nucleoside the Pfizer vaccine uses in place of uridine (U), which is why the patterns are written with Ψ instead of U.
What did the spike protein analysis find?
The spike protein made from the vaccine RNA binds ACE2, an enzyme that contains zinc (Shang et al., 2020). Classen writes that this binding has the potential to release the zinc.
Zinc matters because a 2017 study showed that zinc binding to TDP-43's RNA recognition motif leads to amyloid-like aggregates.
The paper describes two ways this could happen:
- Spike on the surface of a cell that took up the vaccine binds ACE2 on a neighbouring cell, and the complex may be pulled inside
- Or the interaction starts inside a cell that makes ACE2 and has also taken up the vaccine RNA
In plain terms: spike grabs ACE2, ACE2 may let go of its zinc, and zinc is one of the things that can make TDP-43 clump.
What does the paper say about pseudouridine?
The Pfizer vaccine uses a modified nucleoside in place of uridine. Citing FDA briefing documents, Classen writes it was chosen to reduce activation of the innate immune system.
He writes that RNA containing this nucleoside will have altered binding, and that its effect on TDP-43, FUS and other RNA-binding proteins hasn't been published. His concern is that it could potentially make the risky RNA sequences bind TDP-43 and FUS more strongly.
What other risks does the paper raise?
The discussion section goes beyond prion disease. Classen raises these points:
- Spike as a receptor. The vaccine places spike protein in or on host cells, which he writes could act as a receptor for another possibly novel infectious agent.
- How long spike lasts. He writes that public data wasn't available on how long the vaccine RNA is translated or how long spike stays in cells.
- Genetic diversity. Putting the identical spike receptor on everyone's cells removes genetic diversity for at least that receptor, so everyone could become susceptible to the same agent.
- Autoimmunity. He notes COVID-19 infection is associated with autoantibodies and autoimmune disease, making it plausible a vaccine could do the same, and cites work finding spike sequences identical to human proteins, including some in the central nervous system.
- Prion-related findings by others. He cites authors who found prion-related sequences in the SARS-CoV-2 spike that weren't found in related coronaviruses, and a case report of Creutzfeldt-Jakob disease in a man with COVID-19.
The paper also discusses the theory that SARS-CoV-2 is a bioweapon. Classen writes that it's possible the spike protein may have been designed to cause prion disease, raises concerns about privately funded research on activating prion-forming proteins, and states the vaccine could be a bioweapon.
What did the author conclude?
Classen writes that the old medical saying "the cure may be worse than the disease" can apply to vaccines. He concludes that the vaccine RNA has specific sequences that may induce TDP-43 and FUS to fold into their pathologic prion shapes, and that the spike-ACE2 interaction could raise zinc inside cells.
Based on these findings and the other risks he lists, he states his belief that regulatory approval of the RNA vaccines for SARS-CoV-2 was premature and that the vaccine may cause much more harm than benefit.
Related research on our site
Other studies have looked at spike protein and prion-like proteins in different ways. Our explainer on spike amyloid cross-seeding of prion protein and amyloid-beta covers a lab study on spike fragments, and our guide to whether spike protein is a prion covers a review of prion-like regions in spike. For how spike is cut into amyloid-forming pieces, see spike protein amyloid and neutrophil elastase.
If you're looking into symptoms after vaccination, start with our guide to post-vaccination syndrome symptoms. Our at-home microclot test uses Thioflavin T fluorescence microscopy to look at amyloid in a dried blood sample. It provides laboratory observational data for informational and research purposes, isn't a diagnosis, and doesn't detect brain proteins, prions or spike protein. The amyloid fibrin test guide and our overview of types of amyloid tests explain what each kind of test measures.
Frequently asked questions
What does the Classen paper claim about COVID vaccines and prion disease?
It claims the Pfizer vaccine RNA contains sequences that may cause TDP-43 and FUS to fold into their pathologic prion shapes, and that spike binding to ACE2 could release zinc that does the same to TDP-43. Classen links these protein changes to ALS, frontotemporal lobar degeneration and Alzheimer's disease.
What are TDP-43 and FUS?
According to the paper, they're RNA-binding proteins found in both the nucleus and the cytoplasm of cells. They have binding motifs that grab specific RNA sequences. Classen cites research showing that binding certain RNA sequences in the cytoplasm is believed to make them fold in ways that lead to aggregation and prion formation.
What RNA sequences did Classen find in the vaccine?
He reported sixteen UG tandem repeats (ΨGΨG), additional UG-rich sequences and two GGΨA sequences. He also wrote that G-quadruplex sequences are possibly present but would need a more sophisticated computer program to verify. He cites published studies showing these patterns have increased affinity for TDP-43 or FUS.
Why does the paper mention pseudouridine?
The Pfizer vaccine replaces uridine with a modified nucleoside to reduce activation of the innate immune system. Classen writes that RNA containing it will have altered binding, that its effect on TDP-43 and FUS is not published, and that it could potentially enhance binding of sequences that make those proteins take toxic shapes.
Where was the Classen paper published?
In Microbiology & Infectious Diseases, volume 5, issue 1, pages 1 to 3, in 2021. It was received on December 27, 2020 and accepted on February 8, 2021. The full text is open access under a Creative Commons Attribution 4.0 license.
Sources
- COVID-19 RNA Based Vaccines and the Risk of Prion Disease. Microbiology & Infectious Diseases, 2021
- The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Research, 2012
- Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nature Communications, 2016
- The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Research, 2014
- Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nature Neuroscience, 2011
- FUS Recognizes G Quadruplex Structures Within Neuronal mRNAs. Frontiers in Molecular Biosciences, 2020
- Structural basis of receptor recognition by SARS-CoV-2. Nature, 2020
- Zinc binding to RNA recognition motif of TDP-43 induces the formation of amyloid-like aggregates. Scientific Reports, 2017
- Creutzfeldt-Jakob disease in a man with COVID-19: SARS-CoV-2-accelerated neurodegeneration?. Brain, Behavior, and Immunity, 2020
At-Home Amyloid Test
Want vaccine and prion research explained in plain language?
Explore our plain-English guides on spike protein, amyloid and neurodegeneration.
Next steps
- Spike Protein and Alzheimer's: The Spike Amyloid Cross-Seeding StudySpike protein amyloid sped up misfolding of Alzheimer's amyloid-beta and prion protein in a lab study. What it shows about the brain, and what it doesn't.
- Types of Amyloid Tests: Blood Tests, PET, CSF, Biopsy and MicroclotsCompare the types of amyloid tests: Alzheimer's blood tests, amyloid PET, spinal fluid, amyloidosis biopsy and fibrin amyloid microclot microscopy.
- Post-Vaccination Syndrome: Symptoms, Duration and the Spike ResearchPost-vaccination syndrome (post-vaccine syndrome, PVS): symptoms, how long it lasts, and what spike persistence and microclot studies show about the cause.

Tim Ottowitz
Founder & Research Lead
Tim Ottowitz founded Amyloid Test and writes its Science Hub, turning fibrin amyloid and spike protein research into plain-language guides that stay close to the published evidence.
Keep reading

Microclots in Brain: How Amyloid Fibrils Drive COVID Dementia
18.3M-patient study links COVID to dementia. Learn how microclots in brain capillaries and amyloid fibril cascades explain persistent cognitive decline.

Amyloid RNA Delivery: How Seminal Fibrils Shuttle Genetic Cargo
Columbia scientists discovered seminal amyloids shuttle RNA into sperm. Learn how amyloid RNA delivery works and its promise for non-viral gene therapy.

Is Spike Protein a Prion? What a 2026 Prion-Like Domain Review Shows
Is spike protein a prion? A 2026 review links spike prion-like domains to amyloid-beta and tau cross-seeding. Here's what's proven and what isn't yet.